These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21289365)

  • 1. Unity is strength: one, two, or more drugs against advanced pancreatic cancer?
    Reni M; Cereda S; Belli C; Villa E
    Ann Oncol; 2011 Apr; 22(4):987. PubMed ID: 21289365
    [No Abstract]   [Full Text] [Related]  

  • 2. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Bölke E; Peiper M; Budach W
    N Engl J Med; 2008 May; 358(18):1965; author reply 1965. PubMed ID: 18450611
    [No Abstract]   [Full Text] [Related]  

  • 3. [Advances in research on capecitabine as adjuvant treatment for colon cancer after radical resection].
    Zhang SZ
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):801-3. PubMed ID: 21223682
    [No Abstract]   [Full Text] [Related]  

  • 4. [A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].
    Suzuki S; Shigaki N; Yokoyama S; Yamashita H; Sugita H; Arima N
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1545-7. PubMed ID: 21918360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
    Schmoll HJ; Sargent D
    Lancet; 2007 Jul; 370(9582):105-107. PubMed ID: 17630019
    [No Abstract]   [Full Text] [Related]  

  • 6. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Okines AF; Ashley S
    N Engl J Med; 2010 Mar; 362(9):858-9. PubMed ID: 20200397
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
    Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving prognosis after surgery for gastric cancer.
    Nishida T; Doi T
    Lancet Oncol; 2014 Nov; 15(12):1290-2. PubMed ID: 25439685
    [No Abstract]   [Full Text] [Related]  

  • 9. 3rd congress of the International Academy of Oral Oncology.
    Ceschia A
    Lancet Oncol; 2011 Aug; 12(8):732. PubMed ID: 21928491
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
    Farkouh A; Schueller J; Scheithauer W; Czejka M
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
    [No Abstract]   [Full Text] [Related]  

  • 11. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Mayer RJ
    J Clin Oncol; 2007 Sep; 25(27):4165-7. PubMed ID: 17709796
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer: CHRONICLE. A randomised phase III trial of control vs. capecitabine plus oxaliplatin.
    Glynne-Jones R; Meadows H; Wood W
    Clin Oncol (R Coll Radiol); 2007 Jun; 19(5):327-9. PubMed ID: 17434299
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of capecitabine in the management of tumors of the digestive system.
    Gennatas C; Michalaki V; Gennatas S
    Rev Recent Clin Trials; 2009 Jan; 4(1):1-11. PubMed ID: 19149758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine plus oxaliplatin in metastatic colorectal cancer.
    Cassidy J
    J Clin Oncol; 2007 Nov; 25(31):5043-5; author reply 5045-6. PubMed ID: 17971611
    [No Abstract]   [Full Text] [Related]  

  • 15. Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
    Herrmann C; Abel U; Stremmel W; Jaeger D; Herrmann T
    Oncology; 2007; 73(5-6):335-9. PubMed ID: 18497506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comments on final report of the AIO Colorectal Cancer Group Study: fluorouracil/oxaliplatin versus capecitabine/oxaliplatin.
    Buechele T
    J Clin Oncol; 2007 Nov; 25(31):5041-2; author reply 5042-3. PubMed ID: 17971610
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
    Longo F; Mansueto G
    Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
    [No Abstract]   [Full Text] [Related]  

  • 19. Capecitabine combinations in the treatment of advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Nov; 1(3):146-8. PubMed ID: 12450426
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy, which drugs and when.
    Koopman M; Punt CJ
    Eur J Cancer; 2009 Sep; 45 Suppl 1():50-6. PubMed ID: 19775604
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.